Mark Boldin

21.4k citations
52 papers · 16.6k · 10 hit papers · h-index 32

Impact in

  • Cancer Research top 0.02%
    • MicroRNA in disease regulation
    • Cancer-related molecular mechanisms research
    • NF-κB Signaling Pathways
  • Immunology top 0.2%
    • Immune Response and Inflammation
    • interferon and immune responses

Papers in

    • MicroRNA in disease regulation 27
    • Cancer-related molecular mechanisms research 12
    • NF-κB Signaling Pathways 10
    • Circular RNAs in diseases 11
    • Cell death mechanisms and regulation 8

Mark Boldin

52 papers receiving 16.4k citations

Mark Boldin's Hit Papers

miR-146a is a significant brake on autoimmunity, myeloproliferation, and cancer in mice 2011 · 707 citations
7070+10+20Years since publication10002.0k3.0k

Peers

Mark Boldin
Comparison fields: 5 of 132
  • Cancer Research 8.0k
  • Immunology 5.9k
  • Molecular Biology 9.6k
  • Oncology 1.6k
  • Neurology 331
Replace Guido Franzoso with:
Guido Franzoso United States
Amer A. Beg United States
Wen‐Chen Yeh Canada
Ke Zen China
Harald Wajant Germany
Claus Scheidereit Germany
Michael J. May United States
Averil Ma United States
Xin Lin United States
Hiroyasu Nakano Japan
Mark Boldin relative to Guido Franzoso United States Guido Franzoso's profile →
Citations per field
00.5×1.5×2.1×
Guido Franzoso · 1×
Citations per year

Countries citing papers authored by Mark Boldin

Since Specialization
Citations

This map shows the geographic impact of Mark Boldin's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mark Boldin with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mark Boldin more than expected).

Fields of papers citing papers by Mark Boldin

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mark Boldin. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mark Boldin. The network helps show where Mark Boldin may publish in the future.

Co-authors

The 25 scholars most cited alongside Mark Boldin, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Mark Boldin Line = papers co-authored together Mark Boldin links everyone, so they are left out of the graph.

All Works

20 of 20 papers shown

Showing the 20 most-cited of 52 papers — load more, or switch the sort, to bring in the rest.

#Work
1
NF-κB-dependent induction of microRNA miR-146, an inhibitor targeted to signaling proteins of innate immune responses
Hit paper breakdown →
20063621
2
Involvement of MACH, a Novel MORT1/FADD-Interacting Protease, in Fas/APO-1- and TNF Receptor–Induced Cell Death
Hit paper breakdown →
19961993
3
MicroRNA-155 is induced during the macrophage inflammatory response
Hit paper breakdown →
20071556
4
MAP3K-related kinase involved in NF-KB induction by TNF, CD95 and IL-1
Hit paper breakdown →
19971154
5
TUMOR NECROSIS FACTOR RECEPTOR AND Fas SIGNALING MECHANISMS
Hit paper breakdown →
19991095
6
MicroRNAs: new regulators of immune cell development and function
Hit paper breakdown →
2008925
7
A Novel Protein That Interacts with the Death Domain of Fas/APO1 Contains a Sequence Motif Related to the Death Domain
Hit paper breakdown →
1995850
8
Function of miR-146a in Controlling Treg Cell-Mediated Regulation of Th1 Responses
Hit paper breakdown →
2010825
9
miR-146a is a significant brake on autoimmunity, myeloproliferation, and cancer in mice
Hit paper breakdown →
2011707
10
Sustained expression of microRNA-155 in hematopoietic stem cells causes a myeloproliferative disorder
Hit paper breakdown →
2008557
11 1995320
12 2011311
13 2007292
14 2012235
15 2012194
16 1997193
17 2008173
18 2015163
19 2014163
20 2016150

About Mark Boldin

Mark Boldin is a scholar working on Cancer Research, Molecular Biology, Immunology, Oncology and Genetics, having authored 52 papers that have together received 16.6k indexed citations. Recurring topics across this work include MicroRNA in disease regulation (27 papers), Cancer-related molecular mechanisms research (12 papers), Circular RNAs in diseases (11 papers), NF-κB Signaling Pathways (10 papers), Cell death mechanisms and regulation (8 papers), Immune Response and Inflammation (8 papers), interferon and immune responses (7 papers) and Immune Cell Function and Interaction (6 papers). The work is most often cited by research in Cancer Research (8.0k citations), Immunology (5.9k citations), Molecular Biology (9.6k citations), Oncology (1.6k citations) and Neurology (331 citations). Mark Boldin has collaborated with scholars based in United States, Israel and Estonia. Frequent co-authors include David Baltimore, Konstantin D. Taganov, David Wallach, Ryan M. O’Connell, Tanya Goncharov, Nikolay Malinin, Eugene Varfolomeev, Dinesh S. Rao, Genhong Cheng and Igor Mett. Their work appears in journals such as Proceedings of the National Academy of Sciences, Blood, The Journal of Experimental Medicine, The Journal of Cell Biology and Cell.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact